American Society of Hematology/LinkedIn
Oct 1, 2026, 14:39
Understanding the FDA Pathway for Hematology Product Development – American Society of Hematology
American Society of Hematology shared a post on LinkedIn:
“Over the past two days, ASH and the FDA convened the ASH-FDA Collaboration: Workshop on Regulatory Science in Hematology, an interactive program designed to deepen participants’ understanding of the FDA’s role in hematology product development.
Participants explored the FDA’s role in hematology product development through dynamic panels, case studies, and discussions on the IND process, clinical trial design, expanded access, expedited development programs, and regulatory review.
Learn more about the workshop.”

Other posts featuring American Society of Hematology on Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines